Spero Therapeutics Ownership 2024 | Who Owns Spero Therapeutics Now?
Institutional Ownership
25.90%
Insider Ownership
20.38%
Retail Ownership
53.72%
Institutional Holders
48.00
Spero Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ANSON FUNDS MANAGEMENT LP | 7.01% | 0.58% | 3,750,450 | - | - | 4,875,585 | Jun 30, 2024 |
VANGUARD GROUP INC | 3.31% | - | 1,770,525 | 117,093 | 7.08% | 2,301,683 | Jun 30, 2024 |
ACADIAN ASSET MANAGEMENT LLC | 2.00% | 0.00% | 1,071,860 | 309,262 | 40.55% | 1,392,000 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 1.82% | 0.00% | 975,952 | 121,492 | 14.22% | 1,268,738 | Jun 30, 2024 |
ADAR1 CAPITAL MANAGEMENT, LLC | 1.72% | 0.23% | 918,929 | -8,000 | -0.86% | 1,194,608 | Jun 30, 2024 |
ALPHABET INC. | 1.66% | 0.06% | 889,979 | - | - | 1,156,973 | Jun 30, 2024 |
MURCHINSON LTD. | 1.63% | 0.17% | 873,910 | - | - | 1,136,083 | Jun 30, 2024 |
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 1.00% | 0.07% | 535,336 | -72,277 | -11.90% | 695,937 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 0.00% | 492,187 | 22,746 | 4.85% | 639,993 | Jun 30, 2024 |
BLACKROCK INC. | 0.90% | - | 483,402 | 6,506 | 1.36% | 628,423 | Jun 30, 2024 |
NOVO HOLDINGS A/S | 0.88% | 0.04% | 468,902 | - | - | 609,573 | Jun 30, 2024 |
AWM INVESTMENT COMPANY, INC. | 0.62% | 0.06% | 333,400 | - | - | 433,420 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.35% | 0.01% | 184,800 | - | - | 240,240 | Jun 30, 2024 |
STATE STREET CORP | 0.24% | - | 130,511 | - | - | 169,664,000 | Jun 30, 2024 |
DAFNA CAPITAL MANAGEMENT LLC | 0.23% | 0.04% | 125,000 | - | - | 162,500 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.21% | - | 112,303 | -2,256 | -1.97% | 145,994,000 | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 0.18% | 0.00% | 98,518 | -49,354 | -33.38% | 128,073 | Jun 30, 2024 |
MAN GROUP PLC | 0.14% | 0.00% | 73,469 | -140,557 | -65.67% | 95,510 | Jun 30, 2024 |
TWO SIGMA SECURITIES, LLC | 0.13% | 0.00% | 67,728 | 67,728 | 100.00% | 88,046 | Jun 30, 2024 |
MACKENZIE FINANCIAL CORP | 0.06% | 0.00% | 32,729 | 4,287 | 15.07% | 42,548 | Jun 30, 2024 |
Spero Therapeutics's largest institutional shareholder is ANSON FUNDS MANAGEMENT LP, holding 7.01% of the company's total share outstanding, currently valued at $4.88M. The top 10 institutional shareholders own together 21.98% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ANSON FUNDS MANAGEMENT LP | 7.01% | 0.58% | 3,750,450 | - | - | 4,875,585 | Jun 30, 2024 |
ADAR1 CAPITAL MANAGEMENT, LLC | 1.72% | 0.23% | 918,929 | -8,000 | -0.86% | 1,194,608 | Jun 30, 2024 |
MURCHINSON LTD. | 1.63% | 0.17% | 873,910 | - | - | 1,136,083 | Jun 30, 2024 |
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 1.00% | 0.07% | 535,336 | -72,277 | -11.90% | 695,937 | Jun 30, 2024 |
ALPHABET INC. | 1.66% | 0.06% | 889,979 | - | - | 1,156,973 | Jun 30, 2024 |
AWM INVESTMENT COMPANY, INC. | 0.62% | 0.06% | 333,400 | - | - | 433,420 | Jun 30, 2024 |
DAFNA CAPITAL MANAGEMENT LLC | 0.23% | 0.04% | 125,000 | - | - | 162,500 | Jun 30, 2024 |
NOVO HOLDINGS A/S | 0.88% | 0.04% | 468,902 | - | - | 609,573 | Jun 30, 2024 |
DLK INVESTMENT MANAGEMENT, LLC | 0.06% | 0.02% | 31,355 | - | - | 40,762 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.35% | 0.01% | 184,800 | - | - | 240,240 | Jun 30, 2024 |
SHAY CAPITAL LLC | 0.05% | 0.00% | 25,000 | -281,967 | -91.86% | 32,500 | Jun 30, 2024 |
ACADIAN ASSET MANAGEMENT LLC | 2.00% | 0.00% | 1,071,860 | 309,262 | 40.55% | 1,392,000 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 1.82% | 0.00% | 975,952 | 121,492 | 14.22% | 1,268,738 | Jun 30, 2024 |
TWO SIGMA SECURITIES, LLC | 0.13% | 0.00% | 67,728 | 67,728 | 100.00% | 88,046 | Jun 30, 2024 |
WR WEALTH PLANNERS, LLC | 0.00% | 0.00% | 2,600 | - | - | 3,380 | Jun 30, 2024 |
TEXAS YALE CAPITAL CORP. | 0.02% | 0.00% | 10,000 | - | - | 13,000 | Jun 30, 2024 |
MAN GROUP PLC | 0.14% | 0.00% | 73,469 | -140,557 | -65.67% | 95,510 | Jun 30, 2024 |
MACKENZIE FINANCIAL CORP | 0.06% | 0.00% | 32,729 | 4,287 | 15.07% | 42,548 | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 0.18% | 0.00% | 98,518 | -49,354 | -33.38% | 128,073 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 0.00% | 492,187 | 22,746 | 4.85% | 639,993 | Jun 30, 2024 |
The largest Spero Therapeutics shareholder by % of total assets is ANSON FUNDS MANAGEMENT LP. The company owns 3.75M shares of Spero Therapeutics (SPRO), representing 0.58% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ACADIAN ASSET MANAGEMENT LLC | 2.00% | 0.00% | 1,071,860 | 309,262 | 40.55% | 1,392,000 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 1.82% | 0.00% | 975,952 | 121,492 | 14.22% | 1,268,738 | Jun 30, 2024 |
VANGUARD GROUP INC | 3.31% | - | 1,770,525 | 117,093 | 7.08% | 2,301,683 | Jun 30, 2024 |
TWO SIGMA SECURITIES, LLC | 0.13% | 0.00% | 67,728 | 67,728 | 100.00% | 88,046 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 0.00% | 492,187 | 22,746 | 4.85% | 639,993 | Jun 30, 2024 |
BLACKROCK INC. | 0.90% | - | 483,402 | 6,506 | 1.36% | 628,423 | Jun 30, 2024 |
MACKENZIE FINANCIAL CORP | 0.06% | 0.00% | 32,729 | 4,287 | 15.07% | 42,548 | Jun 30, 2024 |
CULLEN/FROST BANKERS, INC. | 0.00% | - | 2,000 | 2,000 | 100.00% | 2,600 | Jun 30, 2024 |
ROYAL BANK OF CANADA | 0.00% | - | 1,959 | 1,959 | 100.00% | 3,000 | Jun 30, 2024 |
FMR LLC | 0.01% | - | 2,889 | 500 | 20.93% | 3,756 | Jun 30, 2024 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 1,000 | 460 | 85.19% | 1,300 | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.01% | - | 5,558 | 366 | 7.05% | 7,225 | Jun 30, 2024 |
ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 295 | 248 | 527.66% | 384 | Jun 30, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | - | 276 | 60 | 27.78% | 359 | Jun 30, 2024 |
CORECAP ADVISORS, LLC | 0.00% | - | 192 | 50 | 35.21% | 250 | Jun 30, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 1 | - | - | 1 | Jun 30, 2024 |
BNP PARIBAS ARBITRAGE, SNC | - | - | 12 | - | - | 16 | Jun 30, 2024 |
JPMORGAN CHASE & CO | 0.00% | - | 236 | - | - | 307 | Jun 30, 2024 |
FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 0.00% | - | 30 | - | - | 39 | Jun 30, 2024 |
US BANCORP \DE\ | 0.00% | - | 151 | - | - | 196 | Jun 30, 2024 |
As of Jun 30 2024, Spero Therapeutics's largest institutional buyer is ACADIAN ASSET MANAGEMENT LLC. The company purchased 309.26K stocks of SPRO, valued at $1.39M.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
SHAY CAPITAL LLC | 0.05% | 0.00% | 25,000 | -281,967 | -91.86% | 32,500 | Jun 30, 2024 |
MAN GROUP PLC | 0.14% | 0.00% | 73,469 | -140,557 | -65.67% | 95,510 | Jun 30, 2024 |
BANK OF MONTREAL /CAN/ | - | - | - | -79,500 | -100.00% | - | Jun 30, 2024 |
SQUAREPOINT OPS LLC | - | - | - | -79,401 | -100.00% | - | Jun 30, 2024 |
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 1.00% | 0.07% | 535,336 | -72,277 | -11.90% | 695,937 | Jun 30, 2024 |
BAILARD, INC. | - | - | - | -60,900 | -100.00% | - | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 0.18% | 0.00% | 98,518 | -49,354 | -33.38% | 128,073 | Jun 30, 2024 |
GSA CAPITAL PARTNERS LLP | - | - | - | -28,319 | -100.00% | - | Jun 30, 2024 |
PRUDENTIAL FINANCIAL INC | - | - | - | -25,400 | -100.00% | - | Jun 30, 2024 |
VIRTU FINANCIAL LLC | - | - | - | -18,180 | -100.00% | - | Jun 30, 2024 |
XTX TOPCO LTD | - | - | - | -15,013 | -100.00% | - | Jun 30, 2024 |
ADAR1 CAPITAL MANAGEMENT, LLC | 1.72% | 0.23% | 918,929 | -8,000 | -0.86% | 1,194,608 | Jun 30, 2024 |
UBS GROUP AG | 0.00% | - | 331 | -5,397 | -94.22% | 430 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.21% | - | 112,303 | -2,256 | -1.97% | 145,994,000 | Jun 30, 2024 |
LAZARD ASSET MANAGEMENT LLC | - | - | - | -1,248 | -100.00% | - | Jun 30, 2024 |
MORGAN STANLEY | 0.01% | - | 6,971 | -928 | -11.75% | 9,062 | Jun 30, 2024 |
IFP ADVISORS, INC | - | - | - | -650 | -100.00% | - | Jun 30, 2024 |
RALEIGH CAPITAL MANAGEMENT INC. | - | - | - | -500 | -100.00% | - | Jun 30, 2024 |
PFS PARTNERS, LLC | - | - | - | -50 | -100.00% | - | Jun 30, 2024 |
ANSON FUNDS MANAGEMENT LP | 7.01% | 0.58% | 3,750,450 | - | - | 4,875,585 | Jun 30, 2024 |
As of Jun 30 2024, Spero Therapeutics's biggest institutional seller is SHAY CAPITAL LLC. The company sold -0.28M shares of SPRO, valued at $32.50K.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
CULLEN/FROST BANKERS, INC. | 0.00% | - | 2,000 | 2,000 | 100.00% | 2,600 | Jun 30, 2024 |
ROYAL BANK OF CANADA | 0.00% | - | 1,959 | 1,959 | 100.00% | 3,000 | Jun 30, 2024 |
Spero Therapeutics's largest new institutional shareholder by number of shares is CULLEN/FROST BANKERS, INC., purchased 2.00K shares, valued at $2.60K, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BANK OF MONTREAL /CAN/ | - | - | - | -79,500 | -100.00% | - | Jun 30, 2024 |
SQUAREPOINT OPS LLC | - | - | - | -79,401 | -100.00% | - | Jun 30, 2024 |
BAILARD, INC. | - | - | - | -60,900 | -100.00% | - | Jun 30, 2024 |
GSA CAPITAL PARTNERS LLP | - | - | - | -28,319 | -100.00% | - | Jun 30, 2024 |
PRUDENTIAL FINANCIAL INC | - | - | - | -25,400 | -100.00% | - | Jun 30, 2024 |
VIRTU FINANCIAL LLC | - | - | - | -18,180 | -100.00% | - | Jun 30, 2024 |
XTX TOPCO LTD | - | - | - | -15,013 | -100.00% | - | Jun 30, 2024 |
LAZARD ASSET MANAGEMENT LLC | - | - | - | -1,248 | -100.00% | - | Jun 30, 2024 |
IFP ADVISORS, INC | - | - | - | -650 | -100.00% | - | Jun 30, 2024 |
RALEIGH CAPITAL MANAGEMENT INC. | - | - | - | -500 | -100.00% | - | Jun 30, 2024 |
PFS PARTNERS, LLC | - | - | - | -50 | -100.00% | - | Jun 30, 2024 |
Spero Therapeutics's largest sold out institutional shareholder by shares sold is BANK OF MONTREAL /CAN/, sold -79.50K shares, valued at -, as of undefined.
Spero Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
Nuveen Multi-Market Income Fund | 0.70% | 486,250 | -1,250 | -0.26% | Mar 31, 2024 |
Core Bond Portfolio | 0.48% | 3,588,710 | -9,370 | -0.26% | Mar 31, 2024 |
CALVERT VARIABLE SERIES INC | 0.47% | 909,625 | -2,375 | -0.26% | Mar 31, 2024 |
CALVERT FUND | 0.31% | 18,344,742 | -47,897 | -0.26% | Mar 31, 2024 |
CALVERT SOCIAL INVESTMENT FUND | 0.27% | 12,337,387 | -32,212 | -0.26% | Mar 31, 2024 |
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust | 0.23% | 957,500 | -2,500 | -0.26% | Feb 29, 2024 |
Nuveen Mortgage & Income Fund/MA/ | 0.22% | 649,687 | - | - | Mar 31, 2024 |
Guggenheim Variable Funds Trust | 0.18% | 750,000 | - | - | Dec 31, 2023 |
JOHN HANCOCK INVESTORS TRUST | 0.18% | 521,157 | 521,157 | - | Jan 31, 2024 |
Calvert Management Series | 0.16% | 1,628,707 | -4,252 | -0.26% | Mar 31, 2024 |
HARBOR FUNDS | 0.15% | 3,403,750 | -8,750 | -0.26% | Jan 31, 2024 |
Guggenheim Variable Funds Trust | 0.12% | 487,500 | -1,250 | -0.26% | Dec 31, 2023 |
GUGGENHEIM STRATEGIC OPPORTUNITIES FUND | 0.10% | 1,962,875 | -5,125 | -0.26% | Feb 29, 2024 |
COMMERCE FUNDS | 0.10% | 1,945,000 | -5,000 | -0.26% | Jan 31, 2024 |
GUGGENHEIM FUNDS TRUST | 0.09% | 54,193,425 | -138,957 | -0.26% | Dec 31, 2023 |
CALVERT SOCIAL INVESTMENT FUND | 0.09% | 4,100,000 | 4,100,000 | - | Mar 31, 2024 |
TIAA-CREF LIFE FUNDS | 0.09% | 243,125 | - | - | Mar 31, 2024 |
CALVERT VARIABLE SERIES INC | 0.09% | 170,000 | 170,000 | - | Mar 31, 2024 |
Touchstone ETF Trust | 0.09% | 344,700 | -900 | -0.26% | Mar 31, 2024 |
BRIDGEWAY FUNDS INC | 0.08% | 184,800 | 50,000 | 37.09% | Mar 28, 2024 |
Voya BALANCED PORTFOLIO INC | 0.07% | 100,000 | 100,000 | - | Mar 31, 2024 |
JOHN HANCOCK BOND TRUST | 0.06% | 4,050,609 | 4,050,609 | - | Feb 29, 2024 |
DoubleLine ETF Trust | 0.05% | 500,000 | 500,000 | - | Mar 31, 2024 |
NUVEEN INVESTMENT FUNDS INC | 0.05% | 1,783,937 | - | - | Jan 31, 2024 |
Catholic Responsible Investments Funds | 0.04% | 1,723,500 | -4,500 | -0.26% | Jan 31, 2024 |
CALVERT FUND | 0.04% | 2,500,000 | 2,500,000 | - | Mar 31, 2024 |
GUGGENHEIM FUNDS TRUST | 0.04% | 23,088,750 | -58,750 | -0.25% | Dec 31, 2023 |
VANGUARD VALLEY FORGE FUNDS | 0.04% | 19,238 | - | - | Mar 31, 2024 |
TIAA-CREF LIFE FUNDS | 0.04% | 99,250 | - | - | Mar 31, 2024 |
JOHN HANCOCK BOND TRUST | 0.04% | 2,448,755 | -6,295 | -0.26% | Feb 29, 2024 |
JOHN HANCOCK SOVEREIGN BOND FUND | 0.04% | 10,409,000 | 10,409,000 | - | Feb 29, 2024 |
JOHN HANCOCK INCOME SECURITIES TRUST | 0.03% | 104,000 | 104,000 | - | Jan 31, 2024 |
NUVEEN INVESTMENT FUNDS INC | 0.03% | 1,042,125 | - | - | Jan 31, 2024 |
Voya FUNDS TRUST | 0.03% | 8,000,000 | 8,000,000 | - | Mar 31, 2024 |
EATON VANCE MUTUAL FUNDS TRUST | 0.03% | 4,672,600 | -12,200 | -0.26% | Mar 31, 2024 |
John Hancock Exchange-Traded Fund Trust | 0.02% | 150,000 | 150,000 | - | Jan 31, 2024 |
GUGGENHEIM FUNDS TRUST | 0.02% | 12,821,760 | 3,912,860 | 43.92% | Dec 31, 2023 |
RiverNorth Funds | 0.02% | 500,000 | - | - | Dec 31, 2023 |
COLLEGE RETIREMENT EQUITIES FUND | 0.02% | 20,082,125 | -51,625 | -0.26% | Mar 31, 2024 |
IndexIQ ETF Trust | 0.01% | 28,758 | - | - | Jan 31, 2024 |
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust | 0.01% | 48,625 | -125 | -0.26% | Feb 29, 2024 |
Legg Mason ETF Investment Trust | 0.01% | 22,851 | - | - | Mar 31, 2024 |
Tidal ETF Trust | 0.01% | 123,165 | - | - | Jan 31, 2024 |
JOHN HANCOCK INVESTMENT TRUST | 0.01% | 741,000 | 741,000 | - | Jan 31, 2024 |
QUANTITATIVE MASTER SERIES LLC | 0.01% | 36,207 | - | - | Mar 31, 2024 |
DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 3,443 | - | - | Mar 31, 2024 |
Destra Investment Trust | 0.01% | 9,383 | - | - | Mar 31, 2024 |
VANGUARD EXPLORER FUND | 0.00% | 54,307 | - | - | Jan 31, 2024 |
Humankind Benefit Corp | 0.00% | 86 | - | - | Dec 31, 2023 |
Federated Hermes MDT Series | 0.00% | 9,473 | - | - | Jan 31, 2024 |
TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 853 | - | - | Mar 31, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 1,608,458 | -525,001 | -24.61% | Mar 31, 2024 |
VANGUARD QUANTITATIVE FUNDS | 0.00% | 17,600 | - | - | Mar 31, 2024 |
TIAA-CREF FUNDS | 0.00% | 11,197,962 | -29,237 | -0.26% | Mar 31, 2024 |
LITMAN GREGORY FUNDS TRUST | 0.00% | 191,500 | 95,500 | 99.48% | Mar 31, 2024 |
TIAA-CREF FUNDS | 0.00% | 8,849,750 | -22,750 | -0.26% | Mar 31, 2024 |
MML Series Investment Fund II | 0.00% | 500,000 | - | - | Dec 31, 2023 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 4,997,677 | -12,847 | -0.26% | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 390,728 | 14,854 | 3.95% | Feb 29, 2024 |
VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 77,605 | - | - | Mar 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 2,941,000 | 2,941,000 | - | Mar 31, 2024 |
NEW COVENANT FUNDS | 0.00% | 5,087 | - | - | Dec 31, 2023 |
DoubleLine Funds Trust | 0.00% | 957,500 | -2,500 | -0.26% | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 28,565 | - | - | Jan 31, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 19,689 | - | - | Mar 31, 2024 |
Calvert Variable Products, Inc. | 0.00% | 1,713 | - | - | Mar 31, 2024 |
Columbia Funds Variable Series Trust II | 0.00% | 19,134 | - | - | Mar 31, 2024 |
VALIC Co II | 0.00% | 17,162 | 200 | 1.18% | Feb 28, 2021 |
COLUMBIA FUNDS SERIES TRUST I | 0.00% | 2,250,000 | 2,250,000 | - | Feb 29, 2024 |
EQ ADVISORS TRUST | 0.00% | 500,000 | - | - | Mar 31, 2024 |
VANGUARD WORLD FUND | 0.00% | 83,035 | - | - | Feb 29, 2024 |
Meeder Funds | 0.00% | 1,609 | - | - | Mar 31, 2024 |
Voya VARIABLE PORTFOLIOS INC | 0.00% | 9,856 | - | - | Mar 31, 2024 |
COLUMBIA FUNDS VARIABLE INSURANCE TRUST | 0.00% | 156,057 | - | - | Mar 31, 2024 |
Direxion Shares ETF Trust | 0.00% | 41,228 | - | - | Jan 31, 2024 |
TIAA-CREF LIFE FUNDS | 0.00% | 683 | - | - | Mar 31, 2024 |
SunAmerica Specialty Series | 0.00% | 122 | - | - | Apr 30, 2021 |
AdvisorShares Trust | 0.00% | 850 | - | - | Mar 28, 2024 |
OLD WESTBURY FUNDS INC | 0.00% | 26,811 | - | - | Jan 31, 2024 |
NATIONWIDE MUTUAL FUNDS | 0.00% | 22,600 | - | - | Jan 31, 2024 |
Global X Funds | 0.00% | 6,714 | - | - | Jan 31, 2024 |
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 725 | - | - | Mar 31, 2024 |
FIDELITY SELECT PORTFOLIOS | 0.00% | 8,552 | - | - | Feb 29, 2024 |
VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 1,163 | - | - | Mar 31, 2024 |
RBB FUND, INC. | 0.00% | 8,900 | - | - | Feb 29, 2024 |
PACE SELECT ADVISORS TRUST | 0.00% | 27,270 | - | - | Jan 31, 2024 |
COLUMBIA FUNDS SERIES TRUST I | 0.00% | 382,877 | - | - | Feb 29, 2024 |
STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 4,893 | - | - | Mar 31, 2024 |
VALIC Co II | 0.00% | 2,462 | - | - | Feb 28, 2021 |
Invesco Exchange-Traded Fund Trust II | 0.00% | 20,317 | - | - | Jan 31, 2024 |
JOHN HANCOCK STRATEGIC SERIES | 0.00% | 461,937 | -1,187 | -0.26% | Feb 29, 2024 |
NORTHERN FUNDS | 0.00% | 9,073 | - | - | Mar 28, 2024 |
JOHN HANCOCK STRATEGIC SERIES | 0.00% | 417,000 | 417,000 | - | Feb 29, 2024 |
RYDEX SERIES FUNDS | 0.00% | 231 | - | - | Dec 31, 2023 |
SA FUNDS INVESTMENT TRUST | 0.00% | 800 | - | - | Mar 31, 2024 |
ProFunds | 0.00% | 517 | - | - | Mar 31, 2024 |
DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 45,205 | - | - | Jan 31, 2024 |
FIDELITY SALEM STREET TRUST | 0.00% | 174,150 | - | - | Mar 31, 2024 |
VANGUARD SCOTTSDALE FUNDS | 0.00% | 78,622 | - | - | Feb 29, 2024 |
T. Rowe Price Index Trust, Inc. | 0.00% | 833 | - | - | Feb 29, 2024 |
Spero Therapeutics's largest mutual fund holder by % of total assets is "Nuveen Multi-Market Income Fund", owning 486.25K shares, compromising 0.70% of its total assets.
Spero Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 24 | 48 | -11.11% |
31 Mar, 24 | 54 | 12.50% |
31 Dec, 23 | 48 | -9.43% |
30 Sep, 23 | 53 | -8.62% |
30 Jun, 23 | 58 | 23.40% |
31 Mar, 23 | 47 | -20.34% |
31 Dec, 22 | 59 | -9.23% |
30 Sep, 22 | 65 | -4.41% |
30 Jun, 22 | 68 | -32.00% |
31 Mar, 22 | 100 | 13.64% |
31 Dec, 21 | 88 | -3.30% |
30 Sep, 21 | 91 | - |
30 Jun, 21 | 91 | -7.14% |
31 Mar, 21 | 98 | 2.08% |
31 Dec, 20 | 96 | 17.07% |
30 Sep, 20 | 82 | 2.50% |
30 Jun, 20 | 80 | 33.33% |
31 Mar, 20 | 60 | -3.23% |
31 Dec, 19 | 62 | 3.33% |
30 Sep, 19 | 60 | - |
30 Jun, 19 | 60 | 9.09% |
31 Mar, 19 | 55 | 7.84% |
31 Dec, 18 | 51 | - |
30 Sep, 18 | 51 | 18.60% |
30 Jun, 18 | 43 | 26.47% |
31 Mar, 18 | 34 | -8.11% |
31 Dec, 17 | 37 | - |
As of 30 Jun 24, 48 institutions are holding Spero Therapeutics's shares, representing a decrease of -11.11% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 24 | 13,861,879 | 0.87% |
31 Mar, 24 | 13,742,012 | -0.56% |
31 Dec, 23 | 13,819,601 | -2.58% |
30 Sep, 23 | 14,186,051 | -1.23% |
30 Jun, 23 | 14,363,122 | 0.79% |
31 Mar, 23 | 14,249,976 | 0.19% |
31 Dec, 22 | 14,222,524 | -28.36% |
30 Sep, 22 | 19,853,143 | -5.27% |
30 Jun, 22 | 20,958,098 | 3.53% |
31 Mar, 22 | 20,242,951 | 2.28% |
31 Dec, 21 | 19,791,509 | 7.73% |
30 Sep, 21 | 18,370,621 | 5.07% |
30 Jun, 21 | 17,484,841 | -5.76% |
31 Mar, 21 | 18,553,801 | -2.82% |
31 Dec, 20 | 19,092,836 | 13.82% |
30 Sep, 20 | 16,774,272 | 42.43% |
30 Jun, 20 | 11,777,176 | 2.13% |
31 Mar, 20 | 11,531,300 | 6.59% |
31 Dec, 19 | 10,818,849 | 4.27% |
30 Sep, 19 | 10,375,439 | -2.51% |
30 Jun, 19 | 10,642,352 | 14.23% |
31 Mar, 19 | 9,316,827 | 2.39% |
31 Dec, 18 | 9,099,360 | -15.35% |
30 Sep, 18 | 10,749,500 | 32.36% |
30 Jun, 18 | 8,121,131 | 5.40% |
31 Mar, 18 | 7,704,972 | -0.69% |
31 Dec, 17 | 7,758,866 | - |
Spero Therapeutics (SPRO) has 13.86M shares outstanding as of 30 Jun 24, up 0.87% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 24 | 25.90% | 3.81% |
31 Mar, 24 | 26.07% | 3.79% |
31 Dec, 23 | 26.22% | 3.60% |
30 Sep, 23 | 26.98% | 3.61% |
30 Jun, 23 | 27.34% | 3.72% |
31 Mar, 23 | 27.13% | 1.89% |
31 Dec, 22 | 37.84% | 1.24% |
30 Sep, 22 | 55.33% | 1.37% |
30 Jun, 22 | 63.55% | 1.65% |
31 Mar, 22 | 62.08% | 1.51% |
31 Dec, 21 | 64.06% | 1.96% |
30 Sep, 21 | 57.17% | 1.65% |
30 Jun, 21 | 58.92% | 1.48% |
31 Mar, 21 | 63.08% | 1.30% |
31 Dec, 20 | 69.76% | 1.19% |
30 Sep, 20 | 76.48% | 2.35% |
30 Jun, 20 | 57.08% | 1.64% |
31 Mar, 20 | 58.96% | 1.66% |
31 Dec, 19 | 59.57% | 1.93% |
30 Sep, 19 | 55.61% | 1.53% |
30 Jun, 19 | 60.24% | 2.06% |
31 Mar, 19 | 54.10% | 2.06% |
31 Dec, 18 | 51.30% | 1.36% |
30 Sep, 18 | 61.53% | 1.93% |
30 Jun, 18 | 56.49% | 1.96% |
31 Mar, 18 | 53.62% | 0.77% |
31 Dec, 17 | 83.66% | - |
As of 30 Jun 24, Spero Therapeutics is held by 25.90% institutional shareholders, representing a 3.81% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 24 | 17 | -29.17% |
31 Mar, 24 | 24 | 71.43% |
31 Dec, 23 | 14 | -12.50% |
30 Sep, 23 | 16 | -30.43% |
30 Jun, 23 | 23 | 21.05% |
31 Mar, 23 | 19 | -32.14% |
31 Dec, 22 | 28 | 16.67% |
30 Sep, 22 | 24 | -27.27% |
30 Jun, 22 | 33 | -19.51% |
31 Mar, 22 | 41 | 20.59% |
31 Dec, 21 | 34 | 13.33% |
30 Sep, 21 | 30 | -30.23% |
30 Jun, 21 | 43 | 7.50% |
31 Mar, 21 | 40 | -31.03% |
31 Dec, 20 | 58 | 38.10% |
30 Sep, 20 | 42 | -31.15% |
30 Jun, 20 | 61 | 60.53% |
31 Mar, 20 | 38 | 2.70% |
31 Dec, 19 | 37 | 12.12% |
30 Sep, 19 | 33 | -2.94% |
30 Jun, 19 | 34 | 36.00% |
31 Mar, 19 | 25 | -3.85% |
31 Dec, 18 | 26 | -31.58% |
30 Sep, 18 | 38 | 52.00% |
30 Jun, 18 | 25 | 56.25% |
31 Mar, 18 | 16 | -56.76% |
31 Dec, 17 | 37 | - |
17 institutional shareholders have increased their position in SPRO stock as of 30 Jun 24 compared to 24 in the previous quarter (a -29.17% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 24 | 8 | -33.33% |
31 Mar, 24 | 12 | 20.00% |
31 Dec, 23 | 10 | -28.57% |
30 Sep, 23 | 14 | 7.69% |
30 Jun, 23 | 13 | 85.71% |
31 Mar, 23 | 7 | -53.33% |
31 Dec, 22 | 15 | -25.00% |
30 Sep, 22 | 20 | 11.11% |
30 Jun, 22 | 18 | -18.18% |
31 Mar, 22 | 22 | - |
31 Dec, 21 | 22 | -8.33% |
30 Sep, 21 | 24 | 20.00% |
30 Jun, 21 | 20 | -25.93% |
31 Mar, 21 | 27 | 12.50% |
31 Dec, 20 | 24 | 4.35% |
30 Sep, 20 | 23 | 91.67% |
30 Jun, 20 | 12 | -20.00% |
31 Mar, 20 | 15 | 36.36% |
31 Dec, 19 | 11 | -8.33% |
30 Sep, 19 | 12 | 20.00% |
30 Jun, 19 | 10 | -41.18% |
31 Mar, 19 | 17 | 30.77% |
31 Dec, 18 | 13 | 160.00% |
30 Sep, 18 | 5 | -28.57% |
30 Jun, 18 | 7 | 16.67% |
31 Mar, 18 | 6 | - |
31 Dec, 17 | - | - |
8 institutional shareholders have reduced their position in SPRO stock as of 30 Jun 24 compared to 12 in the previous quarter (a -33.33% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 24 | 48 | -11.11% | 13,861,879 | 0.87% | 25.90% | 3.81% | 17 | -29.17% | 8 | -33.33% |
31 Mar, 24 | 54 | 12.50% | 13,742,012 | -0.56% | 26.07% | 3.79% | 24 | 71.43% | 12 | 20.00% |
31 Dec, 23 | 48 | -9.43% | 13,819,601 | -2.58% | 26.22% | 3.60% | 14 | -12.50% | 10 | -28.57% |
30 Sep, 23 | 53 | -8.62% | 14,186,051 | -1.23% | 26.98% | 3.61% | 16 | -30.43% | 14 | 7.69% |
30 Jun, 23 | 58 | 23.40% | 14,363,122 | 0.79% | 27.34% | 3.72% | 23 | 21.05% | 13 | 85.71% |
31 Mar, 23 | 47 | -20.34% | 14,249,976 | 0.19% | 27.13% | 1.89% | 19 | -32.14% | 7 | -53.33% |
31 Dec, 22 | 59 | -9.23% | 14,222,524 | -28.36% | 37.84% | 1.24% | 28 | 16.67% | 15 | -25.00% |
30 Sep, 22 | 65 | -4.41% | 19,853,143 | -5.27% | 55.33% | 1.37% | 24 | -27.27% | 20 | 11.11% |
30 Jun, 22 | 68 | -32.00% | 20,958,098 | 3.53% | 63.55% | 1.65% | 33 | -19.51% | 18 | -18.18% |
31 Mar, 22 | 100 | 13.64% | 20,242,951 | 2.28% | 62.08% | 1.51% | 41 | 20.59% | 22 | - |
31 Dec, 21 | 88 | -3.30% | 19,791,509 | 7.73% | 64.06% | 1.96% | 34 | 13.33% | 22 | -8.33% |
30 Sep, 21 | 91 | - | 18,370,621 | 5.07% | 57.17% | 1.65% | 30 | -30.23% | 24 | 20.00% |
30 Jun, 21 | 91 | -7.14% | 17,484,841 | -5.76% | 58.92% | 1.48% | 43 | 7.50% | 20 | -25.93% |
31 Mar, 21 | 98 | 2.08% | 18,553,801 | -2.82% | 63.08% | 1.30% | 40 | -31.03% | 27 | 12.50% |
31 Dec, 20 | 96 | 17.07% | 19,092,836 | 13.82% | 69.76% | 1.19% | 58 | 38.10% | 24 | 4.35% |
30 Sep, 20 | 82 | 2.50% | 16,774,272 | 42.43% | 76.48% | 2.35% | 42 | -31.15% | 23 | 91.67% |
30 Jun, 20 | 80 | 33.33% | 11,777,176 | 2.13% | 57.08% | 1.64% | 61 | 60.53% | 12 | -20.00% |
31 Mar, 20 | 60 | -3.23% | 11,531,300 | 6.59% | 58.96% | 1.66% | 38 | 2.70% | 15 | 36.36% |
31 Dec, 19 | 62 | 3.33% | 10,818,849 | 4.27% | 59.57% | 1.93% | 37 | 12.12% | 11 | -8.33% |
30 Sep, 19 | 60 | - | 10,375,439 | -2.51% | 55.61% | 1.53% | 33 | -2.94% | 12 | 20.00% |
30 Jun, 19 | 60 | 9.09% | 10,642,352 | 14.23% | 60.24% | 2.06% | 34 | 36.00% | 10 | -41.18% |
31 Mar, 19 | 55 | 7.84% | 9,316,827 | 2.39% | 54.10% | 2.06% | 25 | -3.85% | 17 | 30.77% |
31 Dec, 18 | 51 | - | 9,099,360 | -15.35% | 51.30% | 1.36% | 26 | -31.58% | 13 | 160.00% |
30 Sep, 18 | 51 | 18.60% | 10,749,500 | 32.36% | 61.53% | 1.93% | 38 | 52.00% | 5 | -28.57% |
30 Jun, 18 | 43 | 26.47% | 8,121,131 | 5.40% | 56.49% | 1.96% | 25 | 56.25% | 7 | 16.67% |
31 Mar, 18 | 34 | -8.11% | 7,704,972 | -0.69% | 53.62% | 0.77% | 16 | -56.76% | 6 | - |
31 Dec, 17 | 37 | - | 7,758,866 | - | 83.66% | - | 37 | - | - | - |
Spero Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of Spero Therapeutics's stock was made by Shukla Sath on Aug 06 2024, selling 14,800 shares at $1.32 per share (valued at $19.54K).
Spero Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | 2 | - |
Q2 2024 | 8 | - | - |
Q1 2024 | 6 | 6 | 100.00% |
Q4 2023 | 9 | - | - |
Q3 2023 | 1 | 6 | 16.67% |
Q2 2023 | 1 | - | - |
Q1 2023 | 7 | 4 | 175.00% |
Q4 2022 | - | - | - |
Q3 2022 | 5 | 3 | 166.67% |
Q2 2022 | 2 | - | - |
Q1 2022 | 28 | - | - |
Q4 2021 | 6 | 2 | 300.00% |
Q3 2021 | 24 | - | - |
Q1 2021 | 9 | 5 | 180.00% |
Q4 2020 | 14 | 18 | 77.78% |
Q3 2020 | 3 | 6 | 50.00% |
Q2 2020 | 5 | 8 | 62.50% |
Q1 2020 | 8 | 4 | 200.00% |
Q4 2019 | - | - | - |
Q2 2019 | 6 | - | - |
0 total buy trades, and 2 total sell trades (buy/sell ratio of 0.00%) were made by Spero Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | 2 | - |
Q2 2024 | - | - | - |
Q1 2024 | - | 6 | - |
Q4 2023 | - | - | - |
Q3 2023 | - | 6 | - |
Q2 2023 | - | - | - |
Q1 2023 | - | 4 | - |
Q4 2022 | - | - | - |
Q3 2022 | - | 3 | - |
Q2 2022 | 2 | - | - |
Q1 2022 | 13 | - | - |
Q4 2021 | 4 | 1 | 400.00% |
Q3 2021 | 11 | - | - |
Q1 2021 | - | 5 | - |
Q4 2020 | - | 12 | - |
Q3 2020 | - | 3 | - |
Q2 2020 | - | 4 | - |
Q1 2020 | - | - | - |
Q4 2019 | - | - | - |
Q2 2019 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 2 open market sell trades of Spero Therapeutics's stocks.
SPRO Ownership FAQ
Who Owns Spero Therapeutics?
Spero Therapeutics is owned by institutional shareholders (25.90%), insiders (20.38%), and public (53.72%). The largest institutional shareholder of Spero Therapeutics is ANSON FUNDS MANAGEMENT LP (7.01% of total shares) and the top mutual fund owner is Nuveen Multi-Market Income Fund (0.70% of total shares).
Who are the major institutional shareholders of Spero Therapeutics?
Spero Therapeutics's major institutional shareholders are ANSON FUNDS MANAGEMENT LP, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, and ADAR1 CAPITAL MANAGEMENT, LLC. The top five shareholders own together 15.86% of the company's share outstanding.
How many Spero Therapeutics shareholders are there?
As of Jun 2024, there are 48 institutional shareholders of Spero Therapeutics.
What percentage of Spero Therapeutics is owned by ANSON FUNDS MANAGEMENT LP?
ANSON FUNDS MANAGEMENT LP owns 3.75M shares of Spero Therapeutics, representing 7.01% of the company's total shares outstanding, valued at $4.88M (as of Jun 2024).
What percentage of Spero Therapeutics is owned by VANGUARD GROUP INC?
As of Jun 2024, VANGUARD GROUP INC holds 1.77M shares of Spero Therapeutics (SPRO), compromising 3.31% of the company, valued at $2.3M.
What percentage of Spero Therapeutics is owned by ACADIAN ASSET MANAGEMENT LLC?
ACADIAN ASSET MANAGEMENT LLC is the third largest holder of Spero Therapeutics. The company owns 1.07M of the company's shares outstanding (worth $1.39M).